BC Advantage Funds

Profile Mission & Values History Investment Strategy

Executives Directors Mentors

Advantage Venture Fund Advantage Life Science Fund I Advantage Growth Fund

Advantages Documents Frequently Asked Questions How to Invest News Releases

Investment Criteria Frequently Asked Questions Testimonials Case Studies Entrepreneur's Tools Submit Materials

Advantage
Venture
fund

Advantage
Life Science
Fund I

Advantage
Growth Fund

Aspreva Pharmaceuticals Corporation (23.4X Exit)

OncoGeneX Pharmaceuticals Inc. (NASDAQ:OGXI)

Protox Therapeutics Inc. (TSX-V:PRX)

Tekmira Pharmaceuticals Corp. (TSX:TKM)

Vigil Health Solutions Inc. (TSX-V:VGL)

Xillix Technologies Corp. (3X Exit)

Aspreva Pharmaceuticals Corporation is focused on addressing individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications. BC Advantage Funds invested in Aspreva in 200 and exited the investment in 2006 at a 23.4X return multiple, which won BC Advantage Funds the CVCA Venture Capital Deal of the Year Award.

OncoGeneX Pharmaceuticals Inc. (NASDAQ:OGXI) is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies, designed to inhibit the production of specific proteins associated with treatment resistance, and which are over-produced in response to a variety of cancer treatments.

Protox Therapeutics Inc. (TSX-V:PRX) is at the forefront of developing novel treatments in the emerging field of targeted toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), in the development of therapeutic products for its clinical programs.

Tekmira Pharmaceuticals Corp. (TSX:TKM)is an emerging leader in the advancement of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). In May 2008, Tekmira and Protiva Biotherapeutics combined their businesses to create a company with broad RNAi delivery technology and intellectual property, a deep product pipeline, significant partners and a strong balance sheet.

Vigil Health Solutions Inc. (TSX-V:VGL) offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding aged care market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration.

Xillix Technologies Corp. developed innovative fluorescence endoscopy systems to aid in the detection and localization of cancer. BC Advantage Funds invested in Xillix in 2002 and exited the investment in 2003 generating an approximate 3X return on its investment.